Literature DB >> 16925521

Selective targeting of liposomes to macrophages using a ligand with high affinity for the macrophage scavenger receptor class A.

Patrick C N Rensen1, J C Emile Gras, Eva K Lindfors, Ko Willems van Dijk, J Wouter Jukema, Theo J C van Berkel, Erik A L Biessen.   

Abstract

Macrophages play an important role in inflammatory processes and are crucially involved in the onset and progression of atherosclerosis and tumorigenesis. Therefore, macrophages are regarded as an excellent target for therapeutic intervention. Since the scavenger receptor class A (SRA) is highly expressed on macrophages, we developed in the present study an SRA-specific particulate drug carrier by providing phosphatidylcholine liposomes with a targeting ligand for SRA. To enable firm association with liposomes, the high-affinity SRA ligand decadeoxyguanine was covalently attached via a linker to lithocholic oleate (LCO-dA(2)dG(10)). Incorporation of LCO-dA(10)dG(2) into liposomes resulted in an increased electronegative surface charge and a dramatically enhanced serum clearance (t(1/2) < 2 min versus > 5 h). The LCO-dA(2)dG(10)-induced liposome clearance was fully dependent on SRA, as the clearance could be efficiently inhibited by the SRA competitor polyinosinic acid. LCO-dA(2)dG(10) enhanced the affinity of liposomes for SRA in vivo selectively, since introduction of overall or clustered negative charges by other modifications (e.g. oxidation, inclusion of phosphatidylserine, or exposure of glutamic acid residues) did not affect their serum clearance substantially, albeit that these modifications resulted in an at least equally high negative surface charge. LCO-dA(2)dG(10) also increased the association of liposomes with RAW264.7 cells, resulting in an enhanced intracellular delivery and bioactivity of encapsulated dexamethasone-phosphate. Therefore, the SRA-specificity of LCO-dA(2)dG(10)-liposomes may be applied for the specific delivery of drugs to macrophages, which may be of therapeutic benefit in general inflammatory disorders, atherosclerosis, and tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16925521     DOI: 10.2174/157016306778108893

Source DB:  PubMed          Journal:  Curr Drug Discov Technol        ISSN: 1570-1638


  8 in total

Review 1.  Bone marrow-targeted liposomal carriers.

Authors:  Keitaro Sou; Beth Goins; Babatunde O Oyajobi; Bruno L Travi; William T Phillips
Journal:  Expert Opin Drug Deliv       Date:  2011-01-31       Impact factor: 6.648

2.  Hepatocyte apoptotic bodies encasing nonstructural HCV proteins amplify hepatic stellate cell activation: implications for chronic hepatitis C.

Authors:  R K Gieseler; G Marquitan; M Schlattjan; J-P Sowa; L P Bechmann; J Timm; M Roggendorf; G Gerken; S L Friedman; A Canbay
Journal:  J Viral Hepat       Date:  2010-08-15       Impact factor: 3.728

3.  A FQHPSFI peptide selectively binds to LPS-activated alveolar macrophages and inhibits LPS-induced MIP-2 production.

Authors:  Ning Ding; Hui Xiao; Fang Wang; Lixin Xu; Shouzhang She
Journal:  Inflamm Res       Date:  2010-02-27       Impact factor: 4.575

4.  Targeting the hemoglobin scavenger receptor CD163 in macrophages highly increases the anti-inflammatory potency of dexamethasone.

Authors:  Jonas H Graversen; Pia Svendsen; Frederik Dagnæs-Hansen; Jakob Dal; Gabriele Anton; Anders Etzerodt; Mikkel D Petersen; Peter A Christensen; Holger J Møller; Søren K Moestrup
Journal:  Mol Ther       Date:  2012-05-29       Impact factor: 11.454

5.  Specific Kv1.3 blockade modulates key cholesterol-metabolism-associated molecules in human macrophages exposed to ox-LDL.

Authors:  Yong Yang; Yan-Fu Wang; Xiao-Fang Yang; Zhao-Hui Wang; Yi-Tian Lian; Ying Yang; Xiao-Wei Li; Xiang Gao; Jian Chen; Yan-Wen Shu; Long-Xian Cheng; Yu-Hua Liao; Kun Liu
Journal:  J Lipid Res       Date:  2012-10-24       Impact factor: 5.922

6.  TARGETING OF MACROPHAGE FOAM CELLS IN ATHEROSCLEROTIC PLAQUE USING OLIGONUCLEOTIDE-FUNCTIONALIZED NANOPARTICLES.

Authors:  Gaurav Sharma; Zhi-Gang She; David T Valenta; William B Stallcup; Jeffrey W Smith
Journal:  Nano Life       Date:  2010-09

7.  LXR promotes the maximal egress of monocyte-derived cells from mouse aortic plaques during atherosclerosis regression.

Authors:  Jonathan E Feig; Ines Pineda-Torra; Marie Sanson; Michelle N Bradley; Yuliya Vengrenyuk; Dusan Bogunovic; Emmanuel L Gautier; Daniel Rubinstein; Cynthia Hong; Jianhua Liu; Chaowei Wu; Nico van Rooijen; Nina Bhardwaj; Michael Garabedian; Peter Tontonoz; Edward A Fisher
Journal:  J Clin Invest       Date:  2010-12       Impact factor: 14.808

Review 8.  Recent advance in treatment of atherosclerosis: Key targets and plaque-positioned delivery strategies.

Authors:  Li Li; Sainan Liu; Jianying Tan; Lai Wei; Dimeng Wu; Shuai Gao; Yajun Weng; Junying Chen
Journal:  J Tissue Eng       Date:  2022-03-24       Impact factor: 7.813

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.